Log in

NASDAQ:PTIProteostasis Therapeutics Stock Price, Forecast & News

$1.11
-0.05 (-4.31 %)
(As of 04/8/2020 08:00 AM ET)
Add
Compare
Today's Range
$1.10
Now: $1.11
$1.19
50-Day Range
$0.89
MA: $1.40
$2.00
52-Week Range
$0.61
Now: $1.11
$4.72
Volume562,800 shs
Average Volume1.54 million shs
Market Capitalization$57.88 million
P/E RatioN/A
Dividend YieldN/A
Beta0.99
Proteostasis Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers and develops novel therapeutics to treat cystic fibrosis (CF) and other diseases caused by an imbalance in the proteostasis network. The company's lead product candidates include cystic fibrosis transmembrane conductance regulator (CFTR) modulators comprising PTI-428, an amplifier, which has completed Phase II study; and PTI-801, a third generation corrector molecule and PTI-808, a potentiator molecule, which has completed Phase I study. It has a collaboration agreements with Cystic Fibrosis Foundation, Inc. to research, develop, and commercialize products for the treatment of CF, non-classical CF, and other pulmonary diseases in the United States or the European Union; and Genentech, Inc. for licensing the technology and materials relating to therapeutic small molecule modulators. The company was formerly known as Proteoguard, Inc. and changed its name to Proteostasis Therapeutics, Inc. in September 2007. Proteostasis Therapeutics, Inc. was founded in 2006 and is headquartered in Boston, Massachusetts.
Read More
Proteostasis Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.37 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PTI
CUSIPN/A
Phone617-225-0096

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5 million
Book Value$1.22 per share

Profitability

Net Income$-59,130,000.00

Miscellaneous

Employees48
Market Cap$57.88 million
Next Earnings Date5/13/2020 (Estimated)
OptionableOptionable

Receive PTI News and Ratings via Email

Sign-up to receive the latest news and ratings for PTI and its competitors with MarketBeat's FREE daily newsletter.


Proteostasis Therapeutics (NASDAQ:PTI) Frequently Asked Questions

How has Proteostasis Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Proteostasis Therapeutics' stock was trading at $1.16 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, PTI shares have decreased by 4.3% and is now trading at $1.11. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Proteostasis Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Proteostasis Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Proteostasis Therapeutics.

When is Proteostasis Therapeutics' next earnings date?

Proteostasis Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, May 13th 2020. View our earnings forecast for Proteostasis Therapeutics.

How were Proteostasis Therapeutics' earnings last quarter?

Proteostasis Therapeutics Inc (NASDAQ:PTI) announced its quarterly earnings results on Tuesday, March, 10th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.29) by $0.06. View Proteostasis Therapeutics' earnings history.

What price target have analysts set for PTI?

4 analysts have issued 12-month price targets for Proteostasis Therapeutics' stock. Their forecasts range from $4.00 to $8.00. On average, they anticipate Proteostasis Therapeutics' stock price to reach $5.33 in the next twelve months. This suggests a possible upside of 380.5% from the stock's current price. View analysts' price targets for Proteostasis Therapeutics.

Has Proteostasis Therapeutics been receiving favorable news coverage?

Headlines about PTI stock have trended very negative recently, InfoTrie reports. The research group scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Proteostasis Therapeutics earned a daily sentiment score of -3.3 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news aboutProteostasis Therapeutics.

Are investors shorting Proteostasis Therapeutics?

Proteostasis Therapeutics saw a decline in short interest during the month of March. As of March 13th, there was short interest totaling 3,749,000 shares, a decline of 17.2% from the February 27th total of 4,530,000 shares. Based on an average trading volume of 962,700 shares, the short-interest ratio is presently 3.9 days. Approximately 11.0% of the shares of the stock are sold short. View Proteostasis Therapeutics' Current Options Chain.

Who are some of Proteostasis Therapeutics' key competitors?

What other stocks do shareholders of Proteostasis Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Proteostasis Therapeutics investors own include BHP Group (BHP), Micron Technology (MU), Idera Pharmaceuticals (IDRA), Amarin (AMRN), Rite Aid (RAD), Clearside Biomedical (CLSD), Sorrento Therapeutics (SRNE), vTv Therapeutics (VTVT), Syndax Pharmaceuticals (SNDX) and Clovis Oncology (CLVS).

Who are Proteostasis Therapeutics' key executives?

Proteostasis Therapeutics' management team includes the following people:
  • Ms. Meenu Chhabra, Pres, CEO & Director (Age 47)
  • Dr. Benito Munoz, Chief Scientific Officer (Age 57)
  • Dr. Po-Shun Lee, Exec. VP & Chief Medical Officer (Age 50)
  • Ms. Sandra Zimmerman, VP of Fin., Principal Financial Officer & Principal Accounting Officer
  • Ms. Sheila Gilbride Wilson, Chief Operating Officer

When did Proteostasis Therapeutics IPO?

(PTI) raised $51 million in an IPO on Thursday, February 11th 2016. The company issued 3,900,000 shares at $12.00-$14.00 per share. Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Baird and H.C. Wainwright & Co. were co-managers.

What is Proteostasis Therapeutics' stock symbol?

Proteostasis Therapeutics trades on the NASDAQ under the ticker symbol "PTI."

How do I buy shares of Proteostasis Therapeutics?

Shares of PTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Proteostasis Therapeutics' stock price today?

One share of PTI stock can currently be purchased for approximately $1.11.

How big of a company is Proteostasis Therapeutics?

Proteostasis Therapeutics has a market capitalization of $57.88 million and generates $5 million in revenue each year. The company earns $-59,130,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis. Proteostasis Therapeutics employs 48 workers across the globe. View additional information about Proteostasis Therapeutics.

What is Proteostasis Therapeutics' official website?

The official website for Proteostasis Therapeutics is http://www.proteostasis.com/.

How can I contact Proteostasis Therapeutics?

Proteostasis Therapeutics' mailing address is 80 Guest Street Suite 500, Boston MA, 02135. The company can be reached via phone at 617-225-0096 or via email at [email protected]

This page was last updated on 4/8/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel